Research
Hormonal
Reinitiating semaglutide at the target dose after a treatment gap can lead to adverse effects.
Caution is advised when reinitiating GLP-1 therapy after a gap, especially at target doses.
StrongSupportsmedium confidence
Despite the extended treatment gap, the patient was directed to reinitiate semaglutide at the target dose... which was followed by recurrent, symptomatic nausea and vomiting requiring medical intervention.
Why this rating
The case report provides a clear example of an adverse drug event.
Source
Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report
Olivia Denny et al. · Journal of Pharmacy Practice · 2024
case_studyCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →